Corvus Pharmaceuticals, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
CRVS$11.37+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| | | | | | | | |
|---|---|---|---|---|---|---|---|
| · · Nine Months Ended · | |||||||
| · · September 30, · | |||||||
| · · 2026 · · 2025 · | |||||||
| Cash flows from operating activities · · · · · · | |||||||
| Net loss | | $(51,994) | | $(2,962) | | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | ||
| Depreciation and amortization | | 158 | | 79 | | ||
| Accretion related to marketable securities | | 426 | | (1,084) | | ||
| Stock-based compensation | | 8,088 | | 3,756 | | ||
| Change in fair value of warrant liability | | — | | (27,141) | | ||
| Loss from equity method investment | | 2,199 | | 1,251 | | ||
| Changes in operating assets and liabilities: | | | | | | ||
| Accounts receivable - related party | | 32 | | 43 | | ||
| Prepaid and other current assets | | (1,967) | | 1,145 | | ||
| Operating lease right-of-use asset | | | 276 | | | 250 | |
| Other assets | | | (848) | | | (220) | |
| Accounts payable | | 3,155 | | (608) | | ||
| Accrued and other liabilities | | 2,793 | | 1,996 | | ||
| Operating lease liability | | | (305) | | | (111) | |
| Net cash used in operating activities | | (37,987) | | (23,606) | | ||
| Cash flows from investing activities | | | | | | ||
| Purchases of marketable securities | | (239,858) | | (78,332) | | ||
| Maturities of marketable securities | | 102,304 | | 59,805 | | ||
| Purchases of property and equipment | | (739) | | (149) | | ||
| Investment in Angel Pharmaceuticals | | | (5,000) | | | — | |
| Net cash used in investing activities | | (143,293) | | (18,676) | | ||
| Cash flows from financing activities | | | | | | ||
| Proceeds from issuance of common stock in connection with follow-on public offering, net | | 189,407 | | — | | ||
| Proceeds from the exercise of common stock warrants (includes $4,960 in aggregate gross proceeds from related parties) | | | — | | | 35,745 | |
| Proceeds from exercise of common stock options | | 2,310 | | 664 | | ||
| Net cash provided by financing activities | | 191,717 | | 36,409 | | ||
| Net increase (decrease) in cash and cash equivalents | | 10,437 | | (5,873) | | ||
| Cash and cash equivalents at beginning of the period | | 4,576 | | 8,740 | | ||
| Cash and cash equivalents at end of the period | | $15,013 | | $2,867 | | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.